Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alumis Inc. (ALMS : NSDQ)

• Company Description    Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 224

• Price / Volume Information    Yesterday's Closing Price: $9.80 Daily Weekly Monthly 20 Day Moving Average: 3,438,545 shares Shares Outstanding: 129.43 (millions) Market Capitalization: $1,268.46 (millions) Beta: -0.81 52 Week High: $31.35 52 Week Low: $3.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -61.64% -61.08% 12 Week -57.48% -58.69% Year To Date 0.41% -9.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 280 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-231-6625 fax: - ir@alumis.com http://www.alumis.com

• General Corporate Information    Officers Martin Babler - President and Chief Executive Officer; Chairman of John Schroer - Chief Financial Officer Sanam Pangali - Chief Legal Officer and Corporate Secretary Patrick Machado - Director Zhengbin Yao - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 022307102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 129.43 Most Recent Split Date: (:1) Beta: -0.81 Market Capitalization: $1,268.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.79 Price/Cash Flow: - Price / Sales: 171.46 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: -5.41% Sales Growth vs. Year Ago Period: -37.66% vs. Previous Quarter: -4.54% ROE 06/30/26 - -93.15 03/31/26 - -88.79 12/31/25 - -116.97 ROA 06/30/26 - -74.50 03/31/26 - -70.72 12/31/25 - -88.43 Current Ratio 06/30/26 - 6.74 03/31/26 - 7.51 12/31/25 - 4.34 Quick Ratio 06/30/26 - 6.74 03/31/26 - 7.51 12/31/25 - 4.34 Operating Margin 06/30/26 - -5,368.11 03/31/26 - -4,592.50 12/31/25 - -1,628.99 Net Margin 06/30/26 - -5,933.46 03/31/26 - -2,825.70 12/31/25 - -1,011.75 Pre-Tax Margin 06/30/26 - -5,957.21 03/31/26 - -2,927.59 12/31/25 - -1,047.34 Book Value 06/30/26 - 3.52 03/31/26 - 4.46 12/31/25 - 2.88 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©